Beta Drugs quarterly results

·UnclassifiedChart ›

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	137	204	−32.5%
EBITDA	30.3	41.0	−26.2%
EBITDA margin	22.0%	20.1%	+1.9 pts
Profit before tax	25.8	32.1	−19.7%
Net profit	19.3	23.9	−19.4%
EPS	₹16.59	₹47.38	−65.0%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q4 FY25Mar 2025

Expenses
	137	126	94.0	87.3	204	182
	1.7	1.6	2.9	2.3	6.0	4.9
	139	127	96.9	89.6	210	187
	61.8	50.2	36.8	32.5	105	88.0
	−1.1	4.3	−0.7	3.5	−5.5	−1.7
	20.5	20.4	18.7	16.8	19.2	17.7
	1.6	2.6	3.9	4.4	6.9	5.2
	4.6	4.3	4.8	4.4	8.0	6.8
	26.1	23.3	21.5	17.4	44.3	42.3
	113	105	85.0	79.1	177	158
	30.3	27.4	17.7	17.0	41.0	35.8
	25.7	23.0	12.9	12.6	33.0	29.0
Profit
	25.8	22.0	11.8	10.5	32.1	24.2
	0.0	0.0	0.0	0.0	0.0	−4.6
	25.8	22.0	11.8	10.5	32.1	24.2
	6.7	5.8	3.0	2.1	8.5	6.4
	−0.2	−0.3	−0.2	−0.2	−0.4	−0.2
	6.5	5.6	2.8	2.0	8.2	6.2
	19.3	16.5	9.0	8.5	23.9	18.0
	19.3	16.5	9.0	8.5	—	—
	0.0	0.0	0.2	0.0	—	—
	19.3	16.5	9.2	8.5	—	—
	—	—	—	8.5	—	—
	−0.7	−0.7	—	0.0	—	—
Per share
	₹16.59	₹14.78	₹8.93	₹8.40	₹47.38	₹17.81
	₹16.59	₹14.78	₹8.93	₹8.40	₹47.38	₹17.81
Profit build-up — alternate / pre-Ind-AS tags
	—	—	—	—	32.1	28.8
	—	—	—	—	14.9	—
	—	—	—	—	23.9	18.0
Continuing & discontinued operations
	—	—	—	—	23.9	18.0
Other comprehensive income — detail
	—	—	0.2	0.0	—	—
	—	—	0.2	—	—	—
	—	—	—	8.5	—	—
Per share — as-filed variants
	₹16.59	₹14.78	₹8.93	₹8.40	—	—
	₹16.59	₹14.78	₹8.93	₹8.40	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	76.8	71.0	57.9	51.2	105	95.8
	55.9%	56.6%	61.6%	58.7%	51.4%	52.6%
Adjusted (ex-exceptional items) — derived
	25.8	22.0	11.8	10.5	32.1	24.2
	0.0	0.0	0.0	0.0	0.0	−4.6
	19.3	16.5	9.0	8.5	23.9	18.0
	₹16.59	₹14.78	₹8.93	₹8.40	₹47.38	₹17.81

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BETA₹1,849.70

Beta Drugs Limited

· Unclassified

Annual Quarterly₹ CrorePeersTHEJO MACPOWERSAKARSERVOTECHMcap ₹1,875 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q4 FY25 31/03/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	182.1	203.6	87.3	94.0	125.5	137.5
Other Income	4.9	6.0	2.3	2.9	1.6	1.7
Total Income	187.0	209.6	89.6	96.9	127.1	139.2
Expenses
+ Cost of Materials Consumed	88.0	104.5	32.5	36.8	50.2	61.8
+ Changes in Inventories	-1.7	-5.5	3.5	-0.7	4.3	-1.1
+ Employee Benefit Expense	17.7	19.2	16.8	18.7	20.4	20.5
+ Finance Costs	5.2	6.9	4.4	3.9	2.6	1.6
+ Depreciation & Amortisation	6.8	8.0	4.4	4.8	4.3	4.6
+ Other Expenses	42.3	44.3	17.4	21.5	23.3	26.1
Total Expenses	158.2	177.5	79.1	85.0	105.1	113.5
EBITDA	35.8	41.0	17.0	17.7	27.4	30.3
EBIT	29.0	33.0	12.6	12.9	23.0	25.7
Profit
PBT before Exceptional Items	24.2	32.1	10.5	11.8	22.0	25.8
+ Exceptional Items	-4.6	0.0	0.0	0.0	0.0	0.0
Pretax Income	24.2	32.1	10.5	11.8	22.0	25.8
+ Current Tax	6.4	8.5	2.1	3.0	5.8	6.7
+ Deferred Tax	-0.2	-0.4	-0.2	-0.2	-0.3	-0.2
Tax Expense	6.2	8.2	2.0	2.8	5.6	6.5
Net Income	18.0	23.9	8.5	9.0	16.5	19.3
+ Net Income — Continuing Ops	—	—	8.5	9.0	16.5	19.3
+ Other Comprehensive Income	—	—	0.0	0.2	0.0	0.0
Total Comprehensive Income	—	—	8.5	9.2	16.5	19.3
Net Income to Common	—	—	8.5	—	—	—
Minority Interest	—	—	0.0	—	-0.7	-0.7
Per Share
Basic EPS	17.81	47.38	8.40	8.93	14.78	16.59
Diluted EPS	17.81	47.38	8.40	8.93	14.78	16.59
Profit Build-up — Alternate / Pre-Ind-AS Tags
PBT before Exceptional & Extraordinary Items	28.8	32.1	—	—	—	—
+ Adjustments to Profit / (Loss)	—	14.9	—	—	—	—
Profit for the Period before Minority Interest	18.0	23.9	—	—	—	—
Continuing & Discontinued Operations
Profit from Continuing Operations	18.0	23.9	—	—	—	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.0	0.2	—	—
+ Items NOT to be Reclassified to P&L	—	—	—	0.2	—	—
Comprehensive Income — Owners of Parent	—	—	8.5	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	—	8.40	8.93	14.78	16.59
Diluted EPS — Continuing Operations	—	—	8.40	8.93	14.78	16.59
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	95.8	104.6	51.2	57.9	71.0	76.8
Gross Margin %	52.62	51.35	58.70	61.59	56.58	55.88
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	24.2	32.1	10.5	11.8	22.0	25.8
− Exceptional Items (reconciliation)	-4.6	0.0	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	18.0	23.9	8.5	9.0	16.5	19.3
EPS Adj	17.81	47.38	8.40	8.93	14.78	16.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	0.71	0.71	—	—	—	—
Filed Dscr	4.75	8.97	—	—	—	—
Filed Iscr	5.69	11.26	—	—	—	—
Paid Up Equity Capital	10.1	10.1	10.1	10.1	11.1	11.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Beta Drugs Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 22 October 2026 at 11:13 am IST

Beta Drugs (NSE: BETA) reported its Q2 FY27 results (July–September 2026) on Thursday, 22 October 2026 at 11:13 am IST. Consolidated net profit was ₹19.3 crore, down 19.4% from ₹23.9 crore in Q2 FY26 and up 17.0% from ₹16.5 crore in Q1 FY27. Revenue from operations was ₹137 crore, down 32.5% year on year and up 9.5% from the previous quarter.

Q2 FY26 results (a year earlier): 6 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹19.3 Cr−19.4% vs Q2 FY26+17.0% vs Q1 FY27
Revenue from operations: ₹137 Cr−32.5% vs Q2 FY26+9.5% vs Q1 FY27
Operating margin (EBIT): 18.7%+2.4 pts vs Q2 FY26+0.3 pts vs Q1 FY27EBIT ₹25.7 Cr
EBITDA: ₹30.3 Cr−26.2% vs Q2 FY26+10.6% vs Q1 FY27margin 22.0%
Earnings per share (basic): ₹16.59+12.2% vs Q1 FY27
Net profit margin: 14.0%+2.3 pts vs Q2 FY26+0.9 pts vs Q1 FY27

Questions

What was Beta Drugs' net profit in Q2 FY27?

Consolidated net profit was ₹19.3 crore, down 19.4% from ₹23.9 crore in Q2 FY26 and up 17.0% from ₹16.5 crore in Q1 FY27.

What was Beta Drugs' revenue in Q2 FY27?

Revenue from operations was ₹137 crore, down 32.5% year on year and up 9.5% from the previous quarter.

What is Beta Drugs' net profit margin?

Beta Drugs' net profit margin was 14.0% in Q2 FY27 (net profit as a share of revenue from operations), against 11.7% in Q2 FY26 (up 2.3 percentage points). For FY26 as a whole it was 10.8%.

How were Beta Drugs' Q2 FY27 results?

Both fell from a year earlier: net profit was down 19.4% at ₹19.3 crore and revenue was down 32.5% at ₹137 crore. The operating margin was 18.7%, up 2.4 percentage points from 16.2% a year earlier. Against Q1 FY27, net profit was up 17.0% and revenue up 9.5%.

What was Beta Drugs' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹25.7 crore, a margin of 18.7%, against 18.3% in Q1 FY27 and 16.2% in Q2 FY26. EBITDA was ₹30.3 crore, 22.0% of revenue.

How has Beta Drugs' profit changed over the last four quarters?

Net profit by quarter: ₹8.5 crore in Q3 FY26, ₹9 crore in Q4 FY26, ₹16.5 crore in Q1 FY27 and ₹19.3 crore in Q2 FY27. That is ₹53.3 crore over the four quarters. Revenue from operations: ₹87.3 crore, ₹94 crore, ₹126 crore and ₹137 crore.

What was Beta Drugs' EPS in Q2 FY27?

Basic earnings per share were ₹16.59.

What was Beta Drugs' net profit in FY26?

Consolidated net profit was ₹41.5 crore in FY26 (April 2025–March 2026), down 2.2% from ₹42.4 crore in FY25.

What was Beta Drugs' revenue in FY26?

Revenue from operations was ₹385 crore in FY26 (April 2025–March 2026), up 6.2% from ₹362 crore in FY25.

When did Beta Drugs announce its Q2 FY27 results?

On Thursday, 22 October 2026 at 11:13 am IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 6 November 2025.

When will Beta Drugs announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Beta Drugs figures come from?

From Beta Drugs' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 22 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.